FORM 5

QUARTERLY LISTING STATEMENT

Name of Listed Issuer: <u>Ambari Brands Inc.</u>	(the "Issuer").
Trading Symbol: AMB	

This Quarterly Listing Statement must be posted on or before the day on which the Issuer's unaudited interim financial statements are to be filed under the *Securities* Act, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer's first, second and third fiscal quarters. This statement is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the Exchange website.

General Instructions

- (a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Listed Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 Interpretation and General Provisions.

There are three schedules which must be attached to this report as follows:

SCHEDULE A: FINANCIAL STATEMENTS

Financial statements are required as follows:

For the first, second and third financial quarters interim financial statements prepared in accordance with the requirements under Ontario securities law must be attached.

The Issuer's financial statements for the nine months ended September 30, 2023 are attached as Schedule "A".

If the Issuer is exempt from filing certain interim financial statements, give the date of the exempting order.

SCHEDULE B: SUPPLEMENTARY INFORMATION

The supplementary information set out below must be provided when not included in Schedule A.

1. Related party transactions

All related party transactions have been disclosed in the Issuer's financial statements for the nine months ended September 30, 2023 and attached as Schedule "A".

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

- (a) A description of the relationship between the transacting parties. Be as precise as possible in this description of the relationship. Terms such as affiliate, associate or related company without further clarifying details are not sufficient.
- (b) A description of the transaction(s), including those for which no amount has been recorded.
- (c) The recorded amount of the transactions classified by financial statement category.
- (d) The amounts due to or from Related Persons and the terms and conditions relating thereto.
- (e) Contractual obligations with Related Persons, separate from other contractual obligations.
- (f) Contingencies involving Related Persons, separate from other contingencies.

2. Summary of securities issued and options granted during the period.

All securities issued have been disclosed in the notes to the financial statements for the nine months ended September 30, 2023, and attached as Schedule "A". The Issuer has not granted any options.

Provide the following information for the period beginning on the date of the last Listing Statement (Form 2A):

(a) summary of securities issued during the period,

Date of Issue	Type of Security (common shares, convertible debentures , etc.)	Type of Issue (private placement, public offering, exercise of warrants, etc.)	Number	Price	Total Proceeds	Type of Consideration (cash, property, etc.)	Describe relationship of Person with Issuer (indicate if Related Person)	Commission Paid
2023-02-24	Common shares	Private placement	2,000,000	\$0.25	\$500,000	Cash	Unrelated third parties	\$28,000
2023-08-10	Common shares	Exercise of warrants	10,000	\$0.50	\$5,000	Cash	Unrelated third party	Nil
2023-08-16	Common shares	Exercise of warrants	25,000	\$0.50	\$12,500	Cash	Unrelated third party	Nil
2023-08-18	Common shares	Private placement	3,750,000	\$0.40	\$1,500,000	Cash	Unrelated third party	\$95,200
2023-09-08	Common shares	Exercise of Agent Options	531,656	\$0.50	\$265,828	Cash	Unrelated third party	Nil
2023-09-08	Common Shares	Exercise of Agent Options	116,964	-	Nil	Conversion terms	Unrelated third party	Nil

(b) summary of options granted during the period,

	Date	Number	Name of Optionee if Related Person and relationship	Generic description of other Optionees	Exercise Price	Expiry Date	Market Price on date of Grant
ſ							

3. Summary of securities as at the end of the reporting period.

A summary of the securities has been provided in the financial statements for the nine months ended September 30, 2023 and attached as Schedule "A".

Provide the following information in tabular format as at the end of the reporting period:

- (a) description of authorized share capital including number of shares for each class, dividend rates on preferred shares and whether or not cumulative, redemption and conversion provisions,
- (b) number and recorded value for shares issued and outstanding,
- (c) description of options, warrants and convertible securities outstanding, including number or amount, exercise or conversion price and expiry date, and any recorded value, and
- (d) number of shares in each class of shares subject to escrow or pooling agreements or any other restriction on transfer.

As at September 30, 2023, the following common shares of the Issuer were subject to escrow and pooling agreements and other restriction on transfer:

Designation of Class	Number of Securities Held in Escrow or that are Subject to a Contractual Restriction on Transfer	Percentage of Class
Common Shares	6,795,000	12%

Notes:

- (1) Based on 56,528,815 Common Shares issued and outstanding as of the date of the MD&A.
- 4. List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.

Name of Directors/Officers	Position(s) Held						
Avneesh Dhaliwal (Nisha Grewal)	CEO, President, Secretary and Director						
Kate-Lynn Genzel	CFO						
Gurcharn Deol	Director						
Meissam Hagh Panah	Director						

SCHEDULE C: MANAGEMENT DISCUSSION AND ANALYSIS

Provide Interim MD&A if required by applicable securities legislation.

The Issuer's Management Discussion and Analysis for the nine months ended September 30, 2023 is attached as Schedule "B".

Certificate Of Compliance

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.
- 2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
- 4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated November 10, 2023							
		liwal (Nisha Grewal) ctor or Senior Officer					
	" <i>Nisha Grewal</i> " Signature						
	Chief Executive Officer Official Capacity						
Issuer Details	For Quarter	Date of Report					
Name of Issuer	Ended	YY/MM/D					
Ambari Brands Inc.	September 30, 2023	2023/11/10					

Issuer Address						
6th Floor – 905 West Pender Street						
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.				
Vancouver, BC V6C 1L6	N/A	(424) 284-4022				
Contact Name	Contact Position	Contact Telephone No.				
Avneesh Dhaliwal (Nisha Grewal)	CEO	(424) 284-4022				
Contact Email Address	Web Site Address	3				
inquiries@ambaribrands.com https://ambaribeauty.com/						

"Schedule A"

AMBARI BRANDS INC.

Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2023 and 2022

(Expressed in Canadian Dollars)

(Unaudited)

NOTICE TO READER

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed consolidated interim financial statements have been prepared by and are the responsibility of management.

The Company's independent auditor has not performed a review of these condensed consolidated interim financial statements in accordance with the standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity's auditor.

Condensed Consolidated Interim Statements of Financial Position (Expressed in Canadian Dollars) (Unaudited)

	As at September 30, 2023	As at December 31, 2022		
ASSETS				
Current assets				
Cash	\$ 792,618	\$	247,301	
Amounts receivable (Note 5)	89,388		22,922	
Prepaid expenses and deposits (Note 6)	28,068		86,039	
Inventory (Note 7)	669,368		724,351	
	1,579,442		1,080,613	
Non-current assets				
Intangible asset (Note 8)	86,334		-	
Total assets	\$ 1,665,776	\$	1,080,613	
LIABILITIES				
Current liabilities				
Accounts payable and accrued liabilities (Notes 9 and 13)	\$ 138,128	\$	234,127	
SHAREHOLDERS' EQUITY				
Share capital (Note 10)	8,671,213		6,462,334	
Accumulated other comprehensive income (loss)	(499)		2,261	
Reserves (Note 10)	160,662		209,413	
Deficit	(7,303,728)		(5,827,522)	
Total shareholders' equity	1,527,648		846,486	
Total liabilities and shareholders' equity	\$ 1,665,776	\$	1,080,613	

Nature and continuance of operations – Note 1

APPROVED ON BEHALF OF THE BOARD):
---------------------------------	----

"Avneesh Dhaliwal"	Director	"Gurcharn Deol"	Director

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Expressed in Canadian Dollars)

(Unaudited)

	_	Three n Sept	nonth embe		 Nine mont Septemb	
		2023		2022	2023	2022
Revenue (Note 11)	\$	377	\$	68,002	\$ 88,695	\$ 176,176
Cost of sales (Note 7)		5,408		42,731	60,323	77,773
Gross profit (loss)		(5,031)		25,271	28,372	98,403
Expenses						
Advertising and promotion		938,457		137,737	1,126,687	495,375
Consulting fees (Note 13)		10,700		53,693	67,199	118,010
General and administrative (Note 12)		42,762		73,052	132,302	138,524
Professional fees		41,240		73,895	105,263	225,890
Research and development (Note 8)		43,150		5,056	54,841	7,777
Salaries and benefits (Note 13)		2,093		8,367	10,549	25,102
Total expenses		(1,078,402)		(351,800)	(1,496,841)	(1,010,678)
Other Items						
Foreign exchange loss		(7,767)		(4,126)	(7,806)	(4,059)
Interest income		25		4,796	69	13,588
Net loss for the period Exchange difference on translating foreign		(1,091,175)		(325,859)	(1,476,206)	(902,746)
operations		14,277		48,053	(2,760)	54,855
Comprehensive loss for the period	\$	(1,076,898)	\$	(277,806)	\$ (1,478,966)	\$ (847,891)
Loss per common share – basic and diluted	\$	(0.02)	\$	(0.01)	\$ (0.03)	\$ (0.02)
Weighted average number of common						
shares outstanding						
 basic and diluted 		54,020,789		48,534,242	52,341,183	42,973,638

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

	Number of Shares	Share Capital	 ommitment Issue Shares	Com	eumulated Other prehensive ome (Loss)]	Reserves	Deficit	Total
Balance, December 31, 2021	40,473,221	\$ 3,090,622	\$ 3,910,184	\$	(45,160)	\$	209,413	\$ (4,510,115)	\$ 2,654,944
Share repurchase and cancellation									
(Note 10)	(500,000)	(150,000)	-		-		-	-	(150,000)
Conversion of special warrants (Note 10)	11,093,154	3,910,184	(3,910,184)		-		-	=	-
Translation adjustment	-	-	-		54,855		-	-	54,855
Loss for the period	-	-	-		-		-	(902,746)	(902,746)
Balance, September 30, 2022	51,066,375	\$ 6,850,806	\$ 	\$	9,695	\$	209,413	\$ (5,412,861)	\$ 1,657,053
Balance, December 31, 2022	50,095,195	\$ 6,462,334	\$ _	\$	2,261	\$	209,413	\$ (5,827,522)	\$ 846,486
Private placements (Note 10)	5,750,000	2,000,000	_		-		-	-	2,000,000
Share issuance costs (Note 10)	_	(213,318)	_		_		90,118	-	(123,200)
Warrants exercised (Note 10)	35,000	17,500	_		_		-	-	17,500
Agent compensation options exercised									
(Note 10)	648,620	404,697	-		-		(138,869)	-	265,828
Translation adjustment	-	_	_		(2,760)		-	-	(2,760)
Loss for the period	-	-	_		-		-	(1,476,206)	(1,476,206)
Balance, September 30, 2023	56,528,815	\$ 8,671,213	\$ -	\$	(499)	\$	160,662	\$ (7,303,728)	\$ 1,527,648

exercise of agent compensation options

Conversion of special warrants

Condensed Consolidated Interim Statements of Cash Flows (Expressed in Canadian Dollars) (Unaudited)

		Nine months ended September 30, 2023		Nine months ended September 30, 2022
CASH FLOWS PROVIDED BY (USED IN)				
OPERATING ACTIVITIES				
Net loss for the period	\$	(1,476,206)	\$	(902,746)
Items not affecting cash:				
Accrued interest income		-		(11,622)
Foreign exchange gain		-		4,059
Changes in non-cash working capital items:				
Amounts receivable		(66,466)		(25,994)
Prepaid expenses and deposits		57,971		(385,353)
Inventory		54,983		(83,256)
Accounts payable and accrued liabilities		(95,999)		71,013
Net cash used in operating activities		(1,525,717)		(1,333,899)
INVESTING ACTIVITY				
Development of intangible asset		(86,334)		-
EIN ANGING A CENTERS				
FINANCING ACTIVITIES		2 000 000		
Issuance of common shares		2,000,000		(150,000)
Repurchase of common shares Share issuance costs		(122.200)		(150,000)
Proceeds from warrants exercised		(123,200) 17,500		-
Proceeds from agent compensation options exercised		265,828		-
Troceeds from agent compensation options exercised		203,020		
Net cash provided by (used in) financing activities		2,160,128		(150,000)
Foreign exchange on cash		(2,760)		50,796
Change in cash for the period		545,317		(1,433,103)
Cash, beginning of the period		247,301		1,687,620
Cash, end of the period	\$	792,618	\$	254,517
Cash, end of the period	Ф	772,010	Ψ	234,317
Cash paid for interest during the period	\$	-	\$	<u>-</u>
Cash paid for income taxes during the period	\$	-	\$	-
Non-cash transactions affecting cash flows from financing acti	vities:			
		Nine months ended		Nine months ended
		September 30, 2023		September 30, 2022
Fair value of finder's warrants issued	\$	90,118	\$	_
Amounts reclassified from reserves to share capital upon the	4	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	~	
	•	420.000		

The accompanying notes are an integral part of these condensed consolidated interim financial statement.

\$ \$ 138,869

\$

3,910,184

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

1 Nature and continuance of operations

Ambari Brands Inc. (the "Company") was incorporated pursuant to the Business Corporations Act (British Columbia) on June 20, 2019. The Company is a luxury skincare and consumer packaged goods company and has developed a product line on its proprietary "Modern Blend". The Company's common shares trade on the Canadian Securities Exchange (the "CSE") under the trading symbol "AMB", the OTCQB Venture Market under the symbol "AMBBF" and the Frankfurt Stock Exchange under the symbol "Y92". The Company's head office and registered and records office address is 6th Floor – 905 West Pender Street, Vancouver, British Columbia, Canada, V6C 1L6.

These condensed consolidated interim financial statements have been prepared on the basis of accounting principles applicable to a going concern, which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. For the nine months ended September 30, 2023, the Company had negative cash flows from operations of \$1,525,717 (September 30, 2022 - \$1,333,899), a net loss of \$1,476,206 (September 30, 2022 - \$902,746), and as at that date an accumulated deficit of \$7,303,728 (December 31, 2022 - \$5,827,522). As at September 30, 2023, the Company had working capital of \$1,441,314 (December 31, 2022 - \$846,486). These factors indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.

The Company's ability to continue its operations and to realize assets at their carrying values is dependent upon its ability to raise adequate financing from external sources and generate profits and positive cash flows from operations in order to carry out its business objectives. The Company will require additional financing for continuing operations, to evaluate strategic opportunities, and for working capital purposes. However, there is no assurance that the Company will be able to secure such financing on favourable terms. These condensed consolidated interim financial statements do not give effect to any adjustments required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the Company's condensed consolidated interim financial statements. Such adjustments could be material.

Since March 2020, there has been a global pandemic due to the outbreak of COVID-19. The actual and threatened spread of the virus globally has had a material adverse effect on the global economy and, specifically, the regional economies in which the Company operates. The extent to which COVID-19 may impact the Company's business activities will depend on future developments, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions, business disruptions, and the effectiveness of actions taken to contain and treat the disease. These events are highly uncertain and as such, the Company cannot determine their financial impact at this time. COVID-19 may impact the Company's ability to raise future financing.

The Company's business, financial condition, and results of operations may be further negatively affected by economic and other consequences from Russia's military action against Ukraine and the sanctions imposed in response to that action in late February 2022. While the Company expects any direct impacts, of the pandemic and the war in the Ukraine, to the business to be limited, the indirect impacts on the economy and the cosmetics industry and other industries in general could negatively affect the business and may make it more difficult to raise equity or debt financing. There can be no assurance that the Company will not be impacted by adverse consequences that may be brought about on its business, results of operations, financial position, and cash flows in the future.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

2 Basis of preparation

Statement of compliance

These condensed consolidated interim financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS"), including International Accounting Standards ("IAS") 34, *Interim Financial Reporting*, as issued by the International Accounting Standards Board ("IASB"), and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC"). These condensed consolidated interim financial statements do not include all the disclosures required for the annual audited financial statements. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2022.

These condensed consolidated interim financial statements have been prepared on a historical cost basis, except for certain financial instruments, which are stated at fair value. In addition, they have been prepared using the accrual basis of accounting, except for the cash flow information.

The condensed consolidated interim financial statements were approved and authorized for issuance on November 10, 2023 by the Board of Directors.

Basis of consolidation

These condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiary, Ambari Beauty USA, Inc ("Ambari USA"). All inter-company balances, transactions, income, and expenses have been eliminated upon consolidation.

Subsidiaries are entities controlled by the Company. Control exists when the Company has power over an entity, when the Company is exposed, or has rights, to variable returns from the entity and when the Company has the ability to affect those returns through its power over the entity. Subsidiaries are included in the financial results of the Company from the effective date of acquisition up to the effective date of disposition or loss of control.

Foreign currencies

The functional currency is the currency of the primary economic environment in which the entity operates and has been determined for each entity within the Company. The functional currency of the Company is the Canadian dollar ("CAD"). The functional currency of Ambari USA is the Unites States dollar ("USD").

The presentation currency of the Company and Ambari USA is the Canadian dollar.

Accordingly, the accounts of Ambari USA are translated into CAD as follows:

- all of the assets and liabilities are translated at the rate of exchange in effect on the date of the statement of financial position;
- income and expense are translated at the average exchange rate over the reporting period; and
- exchange gains and losses arising from translation are included in accumulated other comprehensive income (loss).

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

2 Basis of preparation (continued)

Foreign currencies (continued)

Transactions occurring in currencies other than the functional currency of the entity in question are recorded at the rate of exchange prevailing on the date of the transaction. Monetary assets and liabilities that are denominated in foreign currencies are translated at the rate prevailing at each reporting date. Non-monetary items that are measured at historical cost in a foreign currency are translated at the exchange rate on the date of the initial transaction. Non-monetary items that are measured at fair values are reported at the exchange rate on the date when fair values are determined. Foreign currency translation differences are recognized in profit or loss.

Use of accounting estimates and judgments

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management's best knowledge of the amount, event or actions, actual results ultimately may differ from those estimates. These condensed consolidated interim financial statements have been prepared using the judgments, estimates and assumptions summarized below.

Going concern

The assessment of the Company's ability to continue as a going concern and to raise sufficient funds to pay its ongoing operating expenditures and to meet its liabilities for the ensuing year, involves significant judgment based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances. The factors considered by management are disclosed in Note 1.

Inventory

Inventory consists of raw materials, work in progress, shipping materials and finished goods recorded at the lower of cost and net realizable value. Inventory represents a significant portion of the asset base of the Company and its value is reviewed at each reporting period. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, expiry, damage, or slow moving. The assessment of whether inventory is slow moving is subject to management's estimates of future sales forecasts and expected shelf lives of inventory. Actual net realizable value can vary from the estimated provision.

Economic recoverability of intangible asset

The Company has determined that intangible asset costs incurred which were capitalized may have future economic benefits and may be economically recoverable. Management uses several criteria in its assessments of economic recoverability and probability of future economic benefits including anticipated cash flows and estimated economic life. The amortization expense related to intangible assets is determined using estimates relating to the useful life of the intangible asset.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

2 Basis of preparation (continued)

Useful lives of intangible asset

Judgement is necessary in determining the date at which an intangible asset is available for its intended use. Also, at each reporting date, management determines whether an intangible asset presents indicators of impairment. For the purposes of its analysis, management uses its judgement considering factors such as the economic environment and the market in which the Company operates, budget forecasts and obsolescence.

3 Significant accounting policies

These condensed consolidated interim financial statements have been prepared, for all periods presented, following the same accounting policies and methods of computation as the Company's audited annual consolidated financial statements for the year ended December 31, 2022, unless noted below, and should be read in conjunction with those annual consolidated financial statements and notes thereto.

Intangible assets

Intangible assets are recognized when it is probable that the use of the asset will generate future economic benefits and the costs of the asset can be determined reliably. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses. Internally generated intangibles, excluding capitalized development costs, are not capitalized and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred. Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure is recognized in net loss as incurred.

Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset when the Company can demonstrate:

- The technical feasibility of completing the intangible asset so that the asset will be available for use or sale
- Its intention to complete and its ability and intention to use or sell the asset
- How the asset will generate future economic benefits
- The availability of resources to complete the asset
- The ability to measure reliably the expenditure during development

Intangible assets that have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses. Intangible assets include costs directly attributable to the development of the Company's software.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

3 Significant accounting policies (continued)

Intangible assets (continued)

Amortization is recognized in profit and loss on a straight-line basis over the estimated useful lives of the finite life intangible assets. Intangible assets in development are not amortized and reflect the cost of developing the intangible asset, which are not yet available for their intended use. Intangible assets in development will start to be amortized when they are available for their intended use. The estimated useful life of the intangible asset is as follows:

Intangible Asset	Period
Scarlett Software ("Scarlett")	5 years

Amortization methods, useful lives and residual values are reviewed at each reporting date and adjusted prospectively, if appropriate.

4 Basis of fair value

Financial instruments that are measured subsequent to initial recognition at fair value are grouped in levels 1 to 3 based on the degree to which the fair value is observable:

- Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 fair value measurements are those derived from inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company uses judgment to select the methods used to make certain assumptions and in performing the fair value calculations in order to determine (a) the values attributed to each component of a transaction at the time of their issuance; (b) the fair value measurements for certain instruments that require subsequent measurement at fair value on a recurring basis; and (c) for disclosing the fair value of financial instruments subsequently carried at amortized cost. These valuation estimates could be significantly different because of the use of judgment and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market.

The Company's financial instruments consist of cash, trade receivables, and accounts payable and accrued liabilities. The Company has no financial instruments carried at fair value.

The carrying value of the Company's financial instruments approximate their fair values due to their short-term maturities.

There were no transfers between the levels of the fair value hierarchy during the nine months ended September 30, 2023 or 2022.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

5 Amounts receivable

		As at December 31, 2022		
Trade receivables	\$	106	\$	2,646
Sales tax receivable		89,282		20,276
	\$	89,388	\$	22,922

6 Prepaid expenses and deposits

		As at December 31, 2022		
Retainers and prepayments for services	\$	26,566	\$	48,277
Deposits on inventory				10,835
Prepaid insurance		1,502		26,927
	\$	28,068	\$	86,039

7 Inventory

	As at September 30, 2023			
Finished goods	\$ 388,673	\$	439,925	
Raw materials	147,967		148,230	
Work in progress	60,719		60,827	
Shipping materials	72,009		75,369	
	\$ 669,368	\$	724,351	

During the nine months ended September 30, 2023, cost of sales includes \$48,488 (September 30, 2022 - \$31,876) of inventory and impairment losses related to inventory of \$185 (September 30, 2022 - \$27,242). The remaining costs of sales comprise of fulfilment costs.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

8 Intangible asset

During the nine months ended September 30, 2023, the Company incurred development costs with respect to an artificial intelligence powered beauty software and application, named "Scarlett". The software will aim to leverage cutting-edge artificial intelligence technology to enhance personalized beauty experiences.

The costs summarized in the table below are considered to be an internally generated intangible asset and were capitalized as such. As of September 30, 2023, the intangible asset was not ready for use and therefore no amortization expense has been recorded as of this date.

Deve	lopment Costs
\$	-
	86,334
\$	86,334
\$	-
	=
\$	-
\$	-
\$	86,334
	\$ \$ \$

During the nine months ended September 30, 2023, research and development expenses include \$43,167 (September 30, 2022 - \$nil) related to "Scarlett" for costs incurred which did not meet the criteria of development costs. The balance of research and development expenses for the nine months ended September 30, 2023 and 2022 relates to the Company's beauty and skincare product line.

9 Accounts payable and accrued liabilities

		As at December 31, 2022	
Trade payables	\$	116,866	\$ 170,439
Accrued and other liabilities		21,262	 63,688
	\$	138,128	\$ 234,127

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

10 Share capital

Authorized

Unlimited common shares, without par value.

Common Shares Held in Escrow

As at September 30, 2023, 6,795,000 common shares (December 31, 2022 – 10,192,500 common shares) were held in escrow and restricted from trading. These common shares will be released from escrow as follows: 1,698,750 common shares released on January 25, 2024, 1,698,750 common shares released on July 25, 2024, 1,698,750 common shares released on July 25, 2025.

Issued, Cancelled, Commitment to Issue

During the nine months ended September 30, 2023:

On February 24, 2023, the Company closed a non-brokered private placement and issued 2,000,000 units of the Company for gross proceeds of \$500,000. Each unit is comprised of one common share of the Company and one-half of one warrant. Each whole warrant is exercisable into one common share of the Company at an exercise price of \$0.35 per common share and expires on February 24, 2024.

The Company paid finder's fees of \$28,000 and issued 112,000 finder's warrants in connection with closing the non-brokered private placement. Each finder's warrant is exercisable into one common share of the Company at an exercise price of \$0.35 per common share and expires on February 24, 2024. The fair value of the finder's warrants was \$27,048 and was determined using the Black Scholes option pricing model using the following assumptions: estimated volatility of 100%, risk-free interest rate of 4.32%, expected life of 1 year, exercise price of \$0.35, a dividend yield of 0%, and a share price of \$0.49.

On August 10, 2023, the Company issued 10,000 common shares pursuant to the exercise of 10,000 warrants for gross proceeds of \$5,000.

On August 16, 2023, the Company issued 25,000 common shares pursuant to the exercise of 25,000 warrants for gross proceeds of \$12,500.

On August 18, 2023, the Company closed a non-brokered private placement and issued 3,750,000 units of the Company for gross proceeds of \$1,500,000. Each unit is comprised of one common share of the Company and one-half of one warrant. Each whole warrant is exercisable into one common share of the Company at an exercise price of \$0.50 per common share and expires on August 18, 2024.

The Company paid finder's fees of \$95,200 and issued 238,000 finder's warrants in connection with closing the non-brokered private placement. Each finder's warrant is exercisable into one common share of the Company at an exercise price of \$0.50 per common share and expires on August 18, 2024. The fair value of the finder's warrants was \$63,070 and was determined using the Black Scholes option pricing model using the following assumptions: estimated volatility of 100%, risk-free interest rate of 4.78%, expected life of 1 year, exercise price of \$0.50, a dividend yield of 0%, and a share price of \$0.59.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

10 Share capital (continued)

Issued, Cancelled, Commitment to Issue (continued)

On September 8, 2023, 531,656 agent compensation options ("ACOs") were exercised for gross proceeds of \$265,828, and as a result the Company issued 648,620 units with each unit consisting of one common share and one-half of one warrant. Each whole warrant is exercisable into one common share of the Company at an exercise price of \$0.75 per common share and expires on July 25, 2024. In connection with the ACOs exercised, \$138,869 was reclassified from reserves to share capital.

During the year ended December 31, 2022:

On March 4, 2022, the Company repurchased and cancelled 500,000 common shares and 250,000 warrants, which were previously issued in connection with a unit private placement completed on February 18, 2020 for consideration of \$150,000 pursuant to a unit purchase agreement.

On July 21, 2022, 9,175,700 special warrants issued during the year ended December 31, 2021 automatically converted in accordance with the underlying terms, and as a result the Company issued 11,093,154 units with each unit comprised of one common share and one-half of one warrant. A total of 5,546,577 warrants were issued with each warrant exercisable into one common share at an exercise price of \$0.75 per common share and expiry of July 25, 2024.

On November 16, 2022, the Company repurchased and cancelled 971,180 common shares with a fair value of \$388,472 in exchange for the settlement of a loan receivable due from the Company's CEO, Avneesh Dhaliwal (Note 13). The loan receivable had a carrying value of \$417,464, including a principal balance of \$388,472 and accrued interest balance of \$28,992. The Company recorded a loss on settlement of \$28,992.

Warrants

	Number of Warrants	Weighted Average Exercise Price
Outstanding, December 31, 2021	4,378,518	\$ 0.50
Issued – Conversion of special warrants	5,546,577	0.75
Cancelled	(250,000)	0.50
Outstanding, December 31, 2022	9,675,095	0.64
Issued – Private placements	2,875,000	0.45
Issued – Finder's warrants	350,000	0.45
Issued – Agent compensation options	324,310	0.75
Exercised	(566,656)	0.50
Outstanding, September 30, 2023	12,657,749	\$ 0.60

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

10 Share capital (continued)

Warrants (continued)

As at September 30, 2023, the following warrants were outstanding:

Outstanding	Exercise Price	Expiry Date	Remaining Life (Years)
202,400(1)	\$0.50	November 9, 2023	0.11
1,112,000	\$0.35	February 24, 2024	0.40
5,870,887	\$0.75	July 25, 2024	0.82
3,359,462	\$0.50	July 25, 2024	0.82
2,113,000	\$0.50	August 18, 2024	0.88

⁽¹⁾ Exercisable into 1.18 units with each whole unit consisting of one common share and one-half of one warrant, each such warrant will be exercisable to acquire one common share at an exercise price of \$0.75 until July 25, 2024.

11 Revenue

The Company generates revenue from the sale of skincare products directly to consumers and to luxury department stores, and on a wholesale basis to distributors and spas.

The Company's revenue disaggregated by primary geographical markets is as follows:

Nine months ended September 30, 2023

	Direct				
	Consumers	Distributors	Retailers	Other	Total
United States	\$ 5,990	\$ 50,908	\$ 7,713	\$ - \$	64,611
European Union	359	23,725	-	-	24,084
	\$ 6,349	\$ 74,633	\$ 7,713	\$ - \$	88,695

Nine months ended September 30, 2022

	Direct				
	Consumers	Distributors	Retailers	Other	Total
United States	\$ 78,479	\$ -	\$ 39,006	\$ 6,885	\$ 124,370
European Union	_	49,092	-	_	49,092
Other	2,714	-	-	-	2,714
	\$ 81,193	\$ 49,092	\$ 39,006	\$ 6,885	\$ 176,176

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

11 Revenue (continued)

For the nine months ended September 30, 2023 and 2022, the following revenue was recorded from customers that comprise 10% or more of revenue:

	Nine months ended September 30,							
		2023	2022					
Customer A	\$	- \$	18,041					
Customer B	\$	50,908 \$	-					
Customer C	\$	23,725 \$	49,092					
Customer D	\$	7,713 \$	20,781					

12 General and administrative expenses

	Three months	ended	September 30,	Nine months ended September 30				
	2023	2022			2023	2022		
Bank charges (recovery)	\$ 4,424	\$	4,977	\$	8,961	\$	19,429	
Dues and subscriptions	4,993		4,492		14,826		12,175	
Insurance	6,403		17,553		47,092		26,402	
Rent	11,904		6,034		20,134		34,229	
Regulatory and filing fees	14,988		38,480		38,998		38,480	
Office expenses	50		1,516		2,291		7,809	
	\$ 42,762	\$	73,052	\$	132,302	\$	138,524	

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

13 Related party transactions and balances

Related party transactions are comprised of services rendered by directors and/or officers of the Company or by a company with a director and/or officer in common. Related party transactions are in the ordinary course of business and are measured at the exchange amount.

Key management compensation

Key management personnel are those having authority and responsibility for planning, directing, and controlling the activities of the Company, directly or indirectly, and include the Company's executive officers and members of the Board of Directors. Key management compensation consisted of the following:

	Three months ended September 30,				Nine months ended September 30,			
	2023		2022		2023		2022	
Consulting fees: Spiral Investment Corp.; a company controlled by Gurcharn Deol, Director 9317-3516 Quebec Inc.; a company	\$ 9,000	\$	9,000	\$	27,000	\$	9,000	
controlled by Meissam Hagh Panah, Director Salaries and benefits: Kate-Lynn Genzel, Chief Financial	1,500		-		4,500		-	
Officer	1,950		7,800		9,750		23,400	
	\$ 12,450	\$	16,800	\$	41,250	\$	32,400	

Loan receivable

On January 4, 2021, the Company entered into a loan agreement for a principal balance of \$388,472 payable by the Company's CEO, Avneesh Dhaliwal (the "CEO Loan Agreement"). The loan was provided to Ms. Dhaliwal for the purpose of purchasing common shares of the Company from former shareholders. The principal balance accrued interest at a rate of 4% per annum. The principal balance and all accrued interest thereon were due within 30 business days of the Company providing written notice of demand to Ms. Dhaliwal. The loan was repayable to the Company at any time without further bonus or penalty.

On November 16, 2022, the Company and Ms. Dhaliwal entered into a share purchase agreement pursuant to which Ms. Dhaliwal returned 971,180 common shares of the Company with a fair value of \$388,472 in exchange for the settlement of the principal balance and accrued interest of the CEO Loan Agreement. 971,180 common shares of the Company were subsequently cancelled and returned to treasury (Note 10). The loan receivable had a carrying value of \$417,464, including a principal balance of \$388,472 and accrued interest balance of \$28,992. The Company recorded a loss on settlement of \$28,992 during the year ended December 31, 2022.

During the three and nine months ended September 30, 2023, the Company accrued interest income with respect to the loan receivable of \$nil (September 30, 2022 - \$3,917) and \$nil (September 30, 2022 - \$11,622), respectively.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

13 Related party transactions and balances (continued)

Accounts payable and accrued liabilities

As at September 30, 2023, accounts payable and accrued liabilities includes \$3,000 (December 31, 2022 - \$18,900) related to consulting fees due to Spiral Investment Corp., a company controlled by Gurcharn Deol, Director. The amount is unsecured, non-interest bearing, and has no fixed terms of repayment.

As at September 30, 2023, accounts payable and accrued liabilities includes \$1,100 (December 31, 2022 - \$602) related to consulting fees due to 9317-3516 Quebec Inc., a company controlled by Meissam Hagh Panah, Director. The amount is unsecured, non-interest bearing, and has no fixed terms of repayment.

As at September 30, 2023, accounts payable and accrued liabilities includes \$nil (December 31, 2022 - \$67) related to general and administration expenses due to Avneesh Dhaliwal, Director, Corporate Secretary and CEO. The amount was unsecured, non-interest bearing, and had no fixed terms of repayment.

14 Capital management

The Company's objective when managing capital is to safeguard its ability to continue as a going concern. The Company manages its capital structure to maximize its financial flexibility making adjustments to it in response to changes in economic conditions and the risk characteristics of the underlying assets and business opportunities. The Company does not presently utilize any quantitative measures to monitor its capital. In order to fund future product developments and pay for general administrative costs, the Company will raise additional amounts as needed.

The Company reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. The Company considers shareholders' equity and working capital as components of its capital base. The Company may access capital through the issuance of shares or the disposition of assets. Management historically funds the Company's expenditures by issuing share capital rather than using capital sources that require fixed repayments of principal and/or interest. The Company is not subject to externally imposed capital requirements and does not have exposure to asset-backed commercial paper or similar products. The Company believes it will be able to raise additional equity capital as required, but recognizes the uncertainty attached thereto. There was no change to the Company's approach to capital management during the nine months ended September 30, 2023.

15 Risk management and liquidity

The Company's risk exposures and the impact on the Company's condensed consolidated interim financial statements are summarized below.

Credit risk

Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and amounts receivable. The risk arises from the non-performance by counterparties of contractual financial obligations. To minimize credit risk, the Company places cash with high credit quality financial institutions. The Company's amounts receivable consist of input tax credits due from the Government of Canada and sales orders due from reputable luxury department stores, distributors, and third party credit card processing services; and as such, amounts receivable are not subject to significant credit risk.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

15 Risk management and liquidity (continued)

Interest rate risk

Interest rate risk is the risk that future cash flows will fluctuate because of changes in market interest rates. The interest earned on cash is insignificant. The Company does not rely on interest income to fund its operations and does not have any interest bearing debt.

Liquidity risk

All of the Company's financial liabilities are classified as current and are anticipated to mature within the next 12 months. The Company intends to settle these with funds from its positive working capital position.

Foreign currency risk

The Company may be exposed to foreign currency risk on fluctuations related to cash balances that are denominated in a foreign currency. As at September 30, 2023, the Company held cash denominated in US dollars of US\$38,707 (December 31, 2022 – US\$10,709) which expose the Company to minimal foreign currency exchange rate risk. The Company currently does not plan to enter into foreign currency future contracts to mitigate this risk as the Company consider this risk to be immaterial.

"SCHEDULE B"

AMBARI BRANDS INC.
Management's Discussion & Analysis
For the nine months ended September 30, 2023 and 2022
(Stated in Canadian Dollars)

This Management's Discussion and Analysis ("MD&A") of Ambari Brands Inc. (the "Company" or "Ambari") is dated November 10, 2023. This MD&A should be read in conjunction with the condensed consolidated interim financial statements and accompanying notes for the nine months ended September 30, 2023 and 2022, which are prepared in accordance with International Financial Reporting Standards ("IFRS"). All amounts are stated in Canadian dollars unless otherwise indicated.

FORWARD LOOKING INFORMATION

This MD&A may contain forward "forward-looking statements" that reflect the Company's current expectations and projections about its future results. Forward-looking statements are statements that are not historical facts, and include, but are not limited to: estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, capital raising initiatives, the impact of industry and macroeconomic factors on the Company's operations, and market opportunities; and statements regarding future performance.

Forward-looking statements used in this MD&A are subject to various risks, uncertainties and other factors, most of which are difficult to predict and are generally beyond the control of the Company. These risks, uncertainties and other factors may include, but are not limited to, those set forth under "*Risk Factors*" contained in the Company's Prospectus dated July 13, 2022 (the "Prospectus") that is available under the Company's profile on SEDAR+ at https://www.sedarplus.ca/.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this MD&A or as of the date otherwise specifically indicated herein. Due to risks, uncertainties and other factors, including the risks, uncertainties and other factors identified in the Prospectus and this MD&A, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by securities law.

CORPORATE OVERVIEW

Ambari Brands Inc. was incorporated under the British Columbia Business Corporations Act on June 20, 2019 and primarily carries on business through its wholly-owned subsidiary, Ambari Beauty USA, Inc. ("Ambari USA"), which was incorporated under the laws of the State of Nevada on September 27, 2019.

The Company's common shares trade on the Canadian Securities Exchange (the "CSE") under the trading symbol "AMB", the OTCQB Venture Market under the symbol "AMBBF" and the Frankfurt Stock Exchange under the symbol "Y92".

The Company's head office and the registered and records office address is 6th Floor – 905 West Pender Street, Vancouver, British Columbia, Canada, V6C 1L6.

DESCRIPTION OF BUSINESS

Ambari is a consumer packaged goods company and has developed a luxury, performance-driven skincare line of products based on its customized "Modern Blend". The formula combines high levels of active ingredients, smart adaptogens and broad-spectrum CBD. The Company's mission is to provide clinical-grade skincare products that provide professional results from the comfort of your home.

To date, the Company has developed four core products – the Gold Profection22 Mask, the PM Active12 Serum, the Complex4 Hydrator Cream and the AM Active10 Essence – all of which are based on the Company's "Modern Blend" concept, which leverages the powerful combination of active ingredients, adaptogens, and broad-spectrum CBD to calm, balance, and transform the skin. In the development of its products, the Company has focused on sourcing high quality, pure ingredients to ensure the cleanest result. All Ambari products are vegan, cruelty-free, and formulated without silicones, parabens, fragrance, or phthalates.

The Company's products are currently sold directly through its e-commerce platform, as well as through select luxury retailers and international distributors.

RECENT DEVELOPMENTS AND OUTLOOK

Corporate

During the nine months ended September 30, 2023, the Company completed two non-brokered private placements for gross proceeds of \$2,000,000, as discussed in "Share Capital". The net proceeds are being used for marketing expenses, general working capital purposes and development of the Scarlett software, as discussed further below.

Distribution

The Company entered into an agreement with FabFitFun (www.fabfitfun.com), one of the largest subscription boxes in the USA, whereby FabFitFun distributed Ambari products to its broad base of users. The Company fulfilled FabFitFun's initial purchase order in the first quarter of fiscal 2023.

Furthering the Company's international expansion which launched in fiscal 2022, the Company entered into an agreement for the distribution of Ambari products in India through e-tailer shops and brick and mortar chains. The Company is currently in the registration process for the sale of its product line in Asia, and once complete, sales are expected to commence. The Company has experienced unexpected delays with the registration process,.

Artificial Intelligence Software Development

In July 2023, the Company commenced research and development towards an artificial intelligence-powered software name "Scarlett" with B2B and consumer applications. The software is intended to provide cutting-edge artificial intelligence technology and augmented reality to further personalize the beauty experiences of customers. The Company hopes that Scarlett will be able to identify and assess customers' skin and provide recommendations of the best products available for their unique individual needs. Additionally, the software will utilize augmented reality by means of a virtual try-on feature allowing the customers to try a wide range of beauty products. A long-term focus of the Company is implementing the technology within the retail sector, to potentially eliminate the need for human beauty advisors and provide customers individualized information within seconds. Further details can be found on the Company's webpage for Scarlett at www.ambari.ai.

In the third quarter of fiscal 2023, the Company assembled the technical team for the development and deployment of Scarlett and continued to make advancements towards completion of the software.

RESULTS OF OPERATIONS

Nine months ended September 30, 2023 and 2022

During the nine months ended September 30, 2023, the Company recorded a net loss of \$1,476,206 (September 30, 2022 - \$902,746). The increase in net loss of \$573,460 is primarily attributable to the Company focusing on the research and development of the Scarlett software and its marketing strategy,. During the nine months ended September 30, 2022, the Company focused on preparations for and filing of a long form prospectus and the process to list on the CSE. The composition and changes within net loss are further discussed below.

Gross profit

The Company recorded revenue for the nine months ended September 30, 2023 of \$88,695 (September 30, 2022 - \$176,176) related to the sale of products directly to consumers, luxury retailers, distributors and wholesalers, as summarized in the table below.

	Nine months ended September 30,								
	2023		2022						
Direct consumers	\$ 6,349	7%	\$	81,193	46%				
Distributors	74,633	84%		49,092	28%				
Retailers	7,713	9%		39,006	22%				
Other	=	0%		6,885	4%				
	\$ 88,695	100%	\$	176,176	100%				

During the nine months ended September 30, 2023, the Company generated decreased total revenue compared to the same period of the prior year while focusing on the expansion of distribution channels, as discussed in "Recent Developments and Outlook". Direct to consumer sales contributed the largest share of total revenue for the nine months ended September 30, 2022 as a result of targeted digital marketing initiatives during the period.

The composition of revenue by product line for the nine months ended September 30, 2023 and 2022 is summarized in the table below.

	Nine months ended September 30,				
	2023	2022			
Gold Profection22 Mask	8%	35%			
PM Active12 Serum	45%	29%			
Complex4 Hydrator Cream	45%	27%			
AM Active10 Essence	2%	7%			
Product bundles	-	2%			
	100%	100%			

The change in the composition of revenue by product line was directly attributable to the shift from individual direct to consumer orders during the nine months ended September 30, 2022 to large quantity purchase orders from distributors during the nine months ended September 30, 2023.

Cost of sales for the nine months ended September 30, 2023 amounted to \$60,323 (September 30, 2022 - \$77,773) and included the inputs to finished goods sold, including raw materials, bottling and packaging, fulfillment costs, and impairment adjustments.

As a result of revenue exceeding the cost of sales, the Company realized a gross profit for the nine months ended September 30, 2023 of \$28,372 (32%). During the nine months ended September 30, 2022, the Company realized a gross profit of \$98,403 (56%). The decrease in gross profit for the nine months ended September 30, 2023 is primarily attributable to the change in composition of revenue and the lower gross margin derived from distribution partners compared to the direct to consumer channel. The Company incurred additional shipping and distribution related costs contributing to the lower gross margin for the nine months ended September 30, 2023.

Expenses

The Company incurred advertising and promotion expenses of \$1,126,687 (September 30, 2022 - \$495,375) during the nine months ended September 30, 2023, representing an increase of \$631,312 compared to the same period of the prior year. During the nine months ended September 30, 2023, the Company began to focus its marketing strategy on comprehensive digital marketing campaigns to heighten market and brand awareness and broaden the Company's reach within the investment community. During the nine months ended September 30, 2022, the Company focused its efforts on digital advertising and strategic partnerships to bolster sales directly to consumers and retailers and identify new international channels.

The Company incurred consulting fees of \$67,199 (September 30, 2022 - \$118,010) during the nine months ended September 30, 2023, representing a decrease of \$50,811 compared to the same period of the prior year. The decrease in consulting fees is a direct result of the Company not renewing certain service agreements with third parties.

The Company incurred general and administrative expenses of \$132,302 (September 30, 2022 - \$138,524) during the nine months ended September 30, 2023, representing a decrease of \$6,222 compared to the same period of the prior year. The decrease in general and administrative expenses is explained by a decrease in bank and merchant fees and inventory storage fees as a result of fewer sales transactions. These decreases in general and administrative expenses were partially offset by increased insurance costs for additional policies implemented.

Professional fees for the nine months ended September 30, 2023 amounted to \$105,263 (September 30, 2022 - \$225,890), representing a decrease of \$120,627. The decrease in professional fees incurred by the Company is due to the preparations for a public listing during the nine months ended September 30, 2022, including the completion of interim review and annual audit engagements by the Company's auditors and preparations of filing documents by the Company's advisors. During the nine months ended September 30, 2023, professional fees comprised public company compliance and maintenance.

The Company incurred research and development expenses of \$54,841 during the nine months ended September 30, 2023 (September 30, 2022 - \$7,777), representing an increase of \$47,064. The increase is a direct result of the commencement of development of the Scarlett software which amounted to \$43,167 (September 30, 2022 - \$nil). The balance of research and development expenses incurred in the nine months ended September 30, 2023 related to dermatologist testing of products which amounted to \$11,674 (September 30, 2022 - \$7,777).

Management's Discussion & Analysis For the nine months ended September 30, 2023 and 2022 (Stated in Canadian Dollars)

The Company incurred salaries and benefits during the nine months ended September 30, 2023 and 2022 of \$10,549 and \$25,102, respectively, in connection with an employment agreement with an officer of the Company. The decrease of \$14,553 is a result of the termination of the employment agreement for several months during the nine months ended September 30, 2023. The employment agreement was later reinstated, and salaries and benefits continued. Refer to "Related Party Transactions".

Other items

The Company recorded interest income for the nine months ended September 30, 2023 of \$69 for interest income earned on the Company's cash balances. During the nine months ended September 30, 2022, the Company recorded interest income of \$13,588 which primarily related to an interest-bearing loan agreement between the Company and Avneesh Dhaliwal, CEO of the Company. Refer to "Related Party Transactions" for additional details of the loan agreement.

Three months ended September 30, 2023 and 2022

During the three months ended September 30, 2023, the Company recorded a net loss of \$1,091,175 (September 30, 2022 - \$325,859). The increase in net loss of \$765,316 is further discussed below.

Gross profit

The Company recorded revenue for the three months ended September 30, 2023 of \$377 (September 30, 2022 - \$68,002) related to the sale of products directly to consumers, luxury retailers, distributors and wholesalers, as summarized in the table below.

	Three months ended September 30,								
	2023		2022						
Direct consumers	\$ 1,278	339%	\$	6,037	9%				
Distributors	-	-		49,092	72%				
Retailers	(901)	(239%)		12,096	18%				
Other	<u> </u>			777	1%				
	\$ 377	100%	\$	68,002	100%				

During the three months ended September 30, 2023, the Company generated decreased total revenue compared to the same period of the prior year while focusing on development of Scarlett, as discussed in "Recent Developments and Outlook". Direct to consumer sales contributed the largest share of total revenue for the three months ended September 30, 2023. During the three months ended September 30, 2022, the Company expanded its distribution to the European Union and focused its efforts on retail expansions, resulting in the increased revenue derived from these channels.

Cost of sales for the three months ended September 30, 2023 amounted to \$5,408 (September 30, 2022 - \$42,731) and included the inputs to finished goods sold, including raw materials, bottling and packaging, fulfillment costs, and impairment adjustments.

As a result of the cost of sales exceeding revenue, the Company realized a gross loss for the three months ended September 30, 2023 of \$5,031 (-1,334%). During the three months ended September 30, 2022, the Company realized a gross profit of \$25,271 (37%). The decrease in gross profit for the three months ended September 30, 2023 is primarily attributable to reduced sales volume in the period, as the Company focused efforts on the digital marketing campaign and development of the Scarlett software.

Expenses

The Company incurred advertising and promotion expenses of \$938,457 (September 30, 2022 - \$137,737) during the three months ended September 30, 2023, representing an increase of \$800,720 compared to the same period of the prior year. During the three months ended September 30, 2023, the Company continued its marketing strategy focused on comprehensive digital marketing campaigns to heighten market and brand awareness and broaden the Company's reach within the investment community. During the three months ended September 30, 2022, the Company focused on strategic partnerships to bolster sales directly to retailers and identify new international channels.

The Company incurred consulting fees of \$10,700 (September 30, 2022 - \$53,693) during the three months ended September 30, 2023, representing a decrease of \$42,993 compared to the same period of the prior year. The decrease in consulting fees is a direct result of the Company not renewing certain service agreements with third parties.

The Company incurred general and administrative expenses of \$42,762 (September 30, 2022 - \$73,052) during the three months ended September 30, 2023, representing a decrease of \$30,290 compared to the same period of the prior year. The decrease in primarily attributable to decreased insurance costs due to changes in policy coverage and lower regulatory and filing fees due to the timing of corporate transactions.

Professional fees for the three months ended September 30, 2023 amounted to \$41,240 (September 30, 2022 - \$73,895), representing a decrease of \$32,655. The decrease in professional fees incurred by the Company is due to the preparations for a public listing in the three months ended September 30, 2022. During the three months ended September 30, 2023, professional fees comprised public company compliance and maintenance.

The Company incurred research and development expenses of \$43,150 during the three months ended September 30, 2023 (September 30, 2022 - \$5,056), representing an increase of \$38,094. The increase is a direct result of the commencement of development of the Scarlett software which amounted to \$43,150 (September 30, 2022 - \$nil). The balance of research and development expenses incurred in the three months ended September 30, 2023 related to dermatologist testing of products which amounted to \$nil (September 30, 2022 - \$5,056).

The Company incurred salaries and benefits during the three months ended September 30, 2023 and 2022 of \$2,093 and \$8,367, respectively, in connection with an employment agreement with an officer of the Company. Refer to "Related Party Transactions".

Other items

The Company recorded interest income for the three months ended September 30, 2023 of \$25 for interest income earned on the Company's cash balances. During the three months ended September 30, 2022, the Company recorded interest income of \$4,796 which primarily related to an interest-bearing loan agreement between the Company and Avneesh Dhaliwal, CEO of the Company. Refer to "*Related Party Transactions*" for additional details of the loan agreement.

SUMMARY OF QUARTERLY RESULTS

The table below sets forth selected results of operations of the Company. All figures are in accordance with IFRS.

For the three months ended	Revenue	Loss for the period	Loss per share (basic and diluted)
September 30, 2023	\$ 377	\$ (1,091,175)	\$ (0.02)
June 30, 2023	\$ 33,451	\$ (210,542)	\$ (0.00)
March 31, 2023	\$ 54,867	\$ (174,489)	\$ (0.00)
December 31, 2022	\$ 27,467	\$ (414,661)	\$ (0.01)
September 30, 2022	\$ 68,002	\$ (325,859)	\$ (0.01)
June 30, 2022	\$ 20,925	\$ (191,339)	\$ (0.00)
March 31, 2022	\$ 87,249	\$ (385,548)	\$ (0.01)
December 31, 2021	\$ 84,059	\$ (1,747,203)	\$ (0.04)

Historical quarterly results of operations and loss per share do not necessarily reflect any recurring expenditure patterns or predictable trends. The Company's expenditures are driven by the availability of financing to fund continued operations. The fluctuation in quarterly revenue correlates to the timing of marketing campaigns, the execution of which tends to drive increased revenue thereafter, and the timing of large quantity distributor orders. The Company incurred an increased loss for the three months ended December 31, 2021 while the Company engaged strategic partners and hosted promotional and media events which showcased the Company's product line with the intention of increasing brand awareness to targeted markets. Thereafter, the Company's operations and quarterly losses for the periods reflect reduced overall operations while the Company focused on expanding its distribution and raising additional working capital. The Company incurred an increased loss for the three months ended September 30, 2023, while the Company engaged strategic partners and focused on digital marketing campaigns to broaden and heighten the Company's brand and investor awareness and commence the development of Scarlett.

CAPITAL RESOURCES AND LIQUIDITY

The Company's working capital as at September 30, 2023 was \$1,441,314 compared to working capital of \$846,486 as at December 31, 2022. The increase in working capital of \$594,828 during the nine months ended September 30, 2023 is due to an increase in cash of \$545,317 as a result of completing financing during the period, net of operating and investing activities as detailed below in "Capital Resources and Liquidity – Cash Flows", an increase in amounts receivable of \$66,466 related to sales tax receivables, and a decrease in accounts payable and accrued liabilities of \$95,999 due to the timing of payments to third parties. These increases to working capital were partially offset by a decrease in prepaid expenses and deposits of \$57,971 due to the timing of payments and agreement terms with third parties and a decrease in inventory of \$54,983 for sales orders fulfilled during the nine months ended September 30, 2023.

Going Concern

The accompanying condensed consolidated interim financial statements have been prepared on the basis of accounting principles applicable to a going concern, which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations.

For the nine months ended September 30, 2023, the Company had negative cash flows from operations of \$1,525,717, a net loss of \$1,476,206, and as at that date an accumulated deficit of \$7,303,728. As at September 30, 2023, the Company had working capital of \$1,441,314. These factors indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.

The Company's ability to continue its operations and to realize assets at their carrying values is dependent upon its ability to raise adequate financing from external sources and generate profits and positive cash flows from operations in order to carry out its business objectives. The Company will require additional financing for continuing operations, to evaluate strategic opportunities, and for working capital purposes. However, there is no assurance that the Company will be able to secure such financing on favorable terms. The accompanying condensed consolidated interim financial statements do not give effect to any adjustments required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the Company's condensed consolidated interim financial statements. Such adjustments could be material.

Cash Flows

The Company's cash flows for the nine months ended September 30, 2023 and 2022 are summarized in the table below.

	Nine months ended September 30,					
	2023		2022			
Cash used in operating activities	\$ (1,525,717)	\$	(1,333,899)			
Cash used in investing activity	(86,334)		-			
Cash provided by (used in) financing activities	2,160,128		(150,000)			
Foreign exchange on cash	(2,760)		50,796			
Change in cash for the period	\$ 545,317	\$	(1,433,103)			
Cash, beginning of the period	247,301		1,687,620			
Cash, end of the period	\$ 792,618	\$	254,517			

In determining cash used in operating activities, the loss reported for the period is adjusted for non-cash items including, but not limited to, accrued interest income and gains and losses on foreign exchange. Cash used in operating activities also reflects changes in working capital items, such as amounts receivable, prepaid expenses and deposits, inventory, and accounts payable and accrued liabilities, which fluctuate in a manner that does not necessarily reflect predictable patterns for the overall use of cash. The generation of working capital is dependent on sources of financing to fund continuing operations.

During the nine months ended September 30, 2023, the Company commenced the research and development phase of the Scarlett software, which resulted in cash used for investing activities of \$86,334. During the nine months ended September 30, 2022, the Company did not have any investing activities.

Cash provided by in financing activities for the nine months ended September 30, 2023 totaled \$2,160,128 and primarily related to two non-brokered private placements for gross proceeds of \$2,000,000, net of share issuance costs of \$123,200. During the nine months ended September 30, 2023, cash provided by warrant exercises amounted to \$283,328. Refer to "Share Capital". Cash used by financing activities for the nine months ended September 30, 2022 of \$150,000 related to the repurchase and cancellation of 500,000 common shares and 250,000 warrants of the Company.

OFF-BALANCE SHEET ARRANGEMENTS

During the reporting periods there were no off-balance sheet arrangements.

RELATED PARTY TRANSACTIONS

Key management personnel are those having authority and responsibility for planning, directing, and controlling the activities of the Company, directly or indirectly, and include the Company's executive officers and members of the Board of Directors. Key management compensation consisted of the following:

	T	Three months ended September 30,			Nine months ended Septem 30,			
		2023		2022		2023		2022
Consulting fees: Spiral Investment Corp.; a company controlled by Gurcharn Deol,								
Director	\$	9,000	\$	9,000	\$	27,000	\$	9,000
9317-3516 Quebec Inc.; a company controlled by Meissam Hagh Panah,								
Director		1,500		-		4,500		-
Salaries and benefits:								
Kate-Lynn Genzel, Chief Financial								
Officer		1,950		7,800		9,750		23,400
	\$	12,450	\$	16,800	\$	41,250	\$	32,400

Loan receivable

On January 4, 2021, the Company entered into a loan agreement for a principal balance of \$388,472 payable by the Company's CEO, Avneesh Dhaliwal (the "CEO Loan Agreement"). The loan was provided to Ms. Dhaliwal for the purpose of purchasing common shares of the Company from former shareholders. The principal balance accrued interest at a rate of 4% per annum. The principal balance and all accrued interest thereon were due within 30 business days of the Company providing written notice of demand to Ms. Dhaliwal. The loan was repayable to the Company at any time without further bonus or penalty.

On November 16, 2022, the Company and the Company's CEO, Avneesh Dhaliwal, entered into a share purchase agreement pursuant to which Ms. Dhaliwal returned 971,180 common shares of the Company with a fair value of \$388,472 in exchange for the settlement of the principal balance and accrued interest of the CEO Loan Agreement. 971,180 common shares of the Company were subsequently cancelled and returned to the treasury.

During the three and nine months ended September 30, 2023, the Company accrued interest income with respect to the loan receivable of \$nil (September 30, 2022 - \$3,917) and \$nil (September 30, 2022 - \$11,622), respectively.

Accounts payable and accrued liabilities

As at September 30, 2023, accounts payable and accrued liabilities includes \$3,000 (December 31, 2022 - \$18,900) related to consulting fees due to Spiral Investment Corp., a company controlled by Gurcharn Deol, Director. The amount is unsecured, non-interest bearing, and has no fixed terms of repayment.

As at September 30, 2023, accounts payable and accrued liabilities includes \$1,100 (December 31, 2022 - \$602) related to consulting fees due to 9317-3516 Quebec Inc., a company controlled by Meissam Hagh Panah, Director. The amount is unsecured, non-interest bearing, and has no fixed terms of repayment.

AMBARI BRANDS INC. Management's Discussion & Analysis For the pine months anded Sentember 30, 2023 and 202

For the nine months ended September 30, 2023 and 2022 (Stated in Canadian Dollars)

As at September 30, 2023, accounts payable and accrued liabilities includes \$nil (December 31, 2022 - \$67) related to general and administration expenses due to Avneesh Dhaliwal, Director, Corporate Secretary and CEO. The amount was unsecured, non-interest bearing, and had no fixed terms of repayment.

Transactions with related parties were measured based on the consideration established and agreed to by the related parties. All services were made on terms equivalent to those that prevail with arm's length transactions.

SHARE CAPITAL

The Company is authorized to issue an unlimited number of common shares without par value.

As at the date of the MD&A:

Security	Number outstanding
Common shares issued	56,528,815
Warrants	12,455,349
	68,984,164

During the nine months ended September 30, 2023:

On February 24, 2023, the Company closed a non-brokered private placement and issued 2,000,000 units of the Company for gross proceeds of \$500,000. Each unit is comprised of one common share of the Company and one-half of one warrant. Each whole warrant is exercisable into one common share of the Company at an exercise price of \$0.35 per common share and expires on February 24, 2024. The Company paid finder's fees of \$28,000 and issued 112,000 finder's warrants in connection with closing the non-brokered private placement. Each finder's warrant is exercisable into one common share of the Company at an exercise price of \$0.35 per common share and expires on February 24, 2024.

On August 10, 2023, the Company issued 10,000 common shares pursuant to the exercise of 10,000 warrants for gross proceeds of \$5,000.

On August 16, 2023, the Company issued 25,000 common shares pursuant to the exercise of 25,000 warrants for gross proceeds of \$12,500.

On August 18, 2023, the Company closed a non-brokered private placement and issued 3,750,000 units of the Company for gross proceeds of \$1,500,000. Each unit is comprised of one common share of the Company and one-half of one warrant. Each whole warrant is exercisable into one common share of the Company at an exercise price of \$0.50 per common share and expired on August 18, 2024. The Company paid finder's fees of \$95,200 and issued 238,000 finder's warrant in connection with closing the non-brokered private placement. Each finder's warrant is exercisable into one common share of the Company at an exercise price of \$0.50 per common share and expires on August 18, 2024.

On September 8, 2023, 531,656 agent compensation options ("ACOs") were exercised for gross proceeds of \$265,828, and as a result the Company issued 648,620 units with each unit consisting of one common share and one-half of one warrant. Each whole warrant is exercisable into one common share of the Company at an exercise price of \$0.75 per common share and expires on July 25, 2024.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management's best knowledge of the amount, event or actions, actual results ultimately may differ from those estimates. The accompanying condensed consolidated interim financial statements have been prepared using the judgments, estimates and assumptions summarized below.

Going concern

The assessment of the Company's ability to continue as a going concern and to raise sufficient funds to pay its ongoing operating expenditures and to meet its liabilities for the ensuing year, involves significant judgment based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances. Refer to "Capital Resources and Liquidity".

Inventory

Inventory consists of raw materials, work in progress, shipping materials, and finished goods recorded at the lower of cost and net realizable value. Inventory represents a significant portion of the asset base of the Company and its value is reviewed at each reporting period. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, expiry, damage, or slow moving. The assessment of whether inventory is slow moving is subject to management's estimates of future sales forecasts and expected shelf lives of inventory. Actual net realizable value can vary from the estimated provision.

Economic recoverability of intangible asset

The Company has determined that intangible asset costs incurred which were capitalized may have future economic benefits and may be economically recoverable. Management uses several criteria in its assessments of economic recoverability and probability of future economic benefits including anticipated cash flows and estimated economic life. The amortization expense related to intangible assets is determined using estimates relating to the useful life of the intangible asset.

Useful lives of intangible asset

Judgement is necessary in determining the date at which an intangible asset is available for its intended use. Also, at each reporting date, management determines whether an intangible asset presents indicators of impairment. For the purposes of its analysis, management uses its judgement considering factors such as the economic environment and the market in which the Company operates, budget forecasts and obsolescence.

ADOPTION OF NEW STANDARDS AND INTERPRETATIONS AND RECENT ACCOUNTING PRONOUNCEMENTS

The Company has reviewed new and revised accounting pronouncements that have been issued but are not yet effective. The Company has not early adopted any new standards and has determined that there are no new standards that are relevant to the Company.

FINANCIAL AND OTHER INSTRUMENTS

Financial instruments that are measured subsequent to initial recognition at fair value are grouped in levels 1 to 3 based on the degree to which the fair value is observable:

- Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 fair value measurements are those derived from inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company uses judgment to select the methods used to make certain assumptions and in performing the fair value calculations in order to determine (a) the values attributed to each component of a transaction at the time of their issuance; (b) the fair value measurements for certain instruments that require subsequent measurement at fair value on a recurring basis; and (c) for disclosing the fair value of financial instruments subsequently carried at amortized cost. These valuation estimates could be significantly different because of the use of judgment and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market.

The Company's financial instruments consist of cash, trade receivables, and accounts payable and accrued liabilities. The Company has no financial instruments carried at fair value.

The carrying value of the Company's financial instruments approximate their fair values due to their short-term maturities.

There were no transfers between the levels of the fair value hierarchy during the nine months ended September 30, 2023 or 2022.

The Company's risk exposures and the impact on the Company's financial instruments are summarized below.

Credit risk

Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and amounts receivable. The risk arises from the non-performance by counterparties of contractual financial obligations. To minimize credit risk, the Company places cash with high credit quality financial institutions. The Company's amounts receivable consists of input tax credits due from the Government of Canada and sales orders due from reputable luxury department stores, distributors, and third party credit card processing services; and as such, amounts receivable are not subject to significant credit risk.

Interest rate risk

Interest rate risk is the risk that future cash flows will fluctuate because of changes in market interest rates. The interest earned on cash is insignificant. The Company does not rely on interest income to fund its operations and does not have any interest-bearing debt.

Liquidity risk

All of the Company's financial liabilities are classified as current and are anticipated to mature within the next 12 months. The Company intends to settle these with funds from its positive working capital position.

The tables below summarize the maturity profile of the Company's financial liabilities.

As at September 30, 2023	Less than 1 year	1-3 years	4 – 5 years	Later than 5 years	Total
Accounts payable and accrued liabilities	\$ 138,128	\$ -	\$ - \$	_	\$ 138,128
Total liabilities	\$ 138,128	\$ =	\$ - \$	-	\$ 138,128

Foreign currency risk

The Company may be exposed to foreign currency risk on fluctuations related to cash balances that are denominated in a foreign currency. As at September 30, 2023, the Company held cash denominated in US dollars of US\$38,707 (December 31, 2022 – US\$10,709) which expose the Company to minimal foreign currency exchange rate risk. The Company currently does not plan to enter into foreign currency future contracts to mitigate this risk as the Company consider this risk to be immaterial.

APPROVAL

The Board of Directors of the Company has approved the disclosure contained in this MD&A.